Valeant Pharmaceuticals cardiovascular news
Valeant said it received subpoenas from the U.S. Attorney’s Offices for the District of Massachusetts and the Southern District of New York. The company said it plans to comply with the subpoenas, which requested information concerning its patient assistance programs, financial support for patients, distribution schemes, communications with CMS and pricing decisions.
Valeant also replied to an inquiry last month from U.S. Sen. Claire McCaskill (D-Mo.). Valeant’s letter contains information about the history, pricing and hospital reimbursement process for Nitropress sodium nitroprusside and Isuprel isoprotenerol and information about its broader pricing rationale and patient access programs. In a statement, McCaskill said Valeant “has been anything but responsive or transparent -- it refused to take any action until served with federal subpoenas, and is still refusing to provide answers to many of the questions I’ve asked.” She said she will continue to investigate drug pricing and to “explore Valeant’s inadequate response.” ...